南京醫藥(600713.SH)擬7224萬元收購恩華和潤70%股權
格隆匯11月29日丨南京醫藥(600713.SH)公佈,為進一步聚焦公司主營業務發展,完善江蘇地區整體業務網絡建設,提高徐州地區以及淮海經濟區市場覆蓋能力,公司擬收購江蘇恩華藥業股份有限公司(以下簡稱“恩華藥業”)及自然人陳支援所持有的江蘇恩華和潤醫藥有限公司(以下簡稱“恩華和潤”)70%股權,收購價格為7224.00萬元。其中:收購恩華藥業所持有的恩華和潤56%股權,收購價格為5779.20萬元;收購陳支援所持有的恩華和潤14%股權,收購價格為1444.80萬元。上述股權交易全部完成後,公司將直接持有恩華和潤70%股權,恩華和潤將納入公司合併報表範圍。
恩華和潤具有較強的儲存配送能力,並有豐富的快批客户配送經驗,可以和公司蘇北區域其他子公司資源聯合,開展更廣泛、更高效的基層客户配送服務並接受第三方委託儲運業務。在零售連鎖方面,恩華和潤將與南京醫藥下屬徐州廣濟連鎖形成批零協同發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.